MK1026-003
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
Learn more about our Cancer Treatment Team by scrolling below, or visit our Meet the Team page.